Skin and oral lesions associated to imatinib mesylate therapy
- BASSO, Fernanda Goncalves
- BOER, Camila Cominato
- CORREA, Maria Elvira Pizzigatti
- TORREZAN, Marcia
- CINTRA, Maria Leticia
- MAGALHAES, Marina H. C. Gallottini de
- SANTOS, Paulo da Silva
- SOUZA, Carmino Antonio de
DOIAbstract
Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph(+) in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy
Add to ORKG